# TNF-alpha adalimumab mechanism

## Adalimumab neutralizes TNF-alpha through high-affinity binding that blocks receptor interaction, while simultaneously inducing apoptosis in transmembrane TNF-alpha-expressing cells via complement-dependent and caspase-mediated mechanisms and modulating intracellular inflammatory pathways including NF-κB signaling and microRNA networks.

## Abstract

Adalimumab functions through five complementary mechanisms to inhibit TNF-alpha activity. Structurally, adalimumab binds TNF-alpha with high affinity (KD 7.05-10 × 10⁻¹¹ M) through a large epitope (2,540 Ų buried surface area) that directly occupies the TNF receptor-binding site, blocking both soluble and transmembrane TNF-alpha. Beyond neutralization, adalimumab induces cytotoxic effects including complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and caspase-3-mediated apoptosis in transmembrane TNF-alpha-expressing cells. Adalimumab modulates intracellular signaling by reversing NF-κB pathway activation and downregulating genes including IKBKB, IRAK1, TRAF2, and MAP3K7, while simultaneously regulating anti-inflammatory microRNAs (miR-1297, miR-30a, miR-126-3p) and pro-inflammatory microRNAs (miR-146a-5p). Cell-type-specific effects include restoration of intracellular TNF-alpha levels in monocytes, CD36 upregulation through NADPH oxidase-mediated redox signaling, suppression of endothelial adhesion molecules, and TNF-RI blockade in osteoclasts.

### Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question.

### Paper search

We performed a semantic search across over 138 million academic papers from the Elicit search engine, which includes all of [Semantic Scholar](https://www.semanticscholar.org/) and [OpenAlex](https://openalex.org/).

### Screening

We screened in sources based on their abstracts that met these criteria:

- **Mechanistic Focus**
- **Mechanistic Measurements**
- **Study Design**
- **Adalimumab Population**
- **Mechanistic Investigation**
- **Adalimumab-Specific Data**
- **Mechanistic Insights**
- **Publication Type**

### Data extraction

We asked a large language model to extract each data column below from each paper:

- **Mechanism Category**
- **Experimental Model**
- **Key Mechanistic Findings**
- **Target Cells/Tissues**
- **Anti-TNF Comparisons**
- **Clinical Relevance**

## Results

### Characteristics of Included Studies

| Study | Full Text Retrieved? | Experimental Model | Mechanism Category | Disease Context |
| --- | --- | --- | --- | --- |
| Aleksandra Plata-Babula et al., 2025 | Yes | HaCaT keratinocytes (in vitro) | Binding/neutralization, Cellular regulation | Psoriasis |
| Shi Hu et al., 2013 | Yes | Crystal structure, E. coli and CHO cells (in vitro) | Binding/neutralization (epitope binding, receptor blockade) | TNF-alpha-associated diseases |
| Carlos Zamora-Atenza et al., 2014 | Yes | Primary monocytes from RA patients and healthy controls (in vitro and human) | Binding/neutralization, Cytotoxic effects, Signal transduction, Cellular regulation, Tissue/organ effects | Rheumatoid arthritis |
| Raghav Oberoi et al., 2016 | Yes | THP-1 macrophages, HUVECs, hypercholesterolemic mice (in vitro and in vivo) | Binding/neutralization, Tissue/organ effects | Atherosclerosis, rheumatoid arthritis |
| H. Mitoma et al., 2008 | No | Jurkat T cells (in vitro) | Binding/neutralization, Cytotoxic effects, Signal transduction | Rheumatoid arthritis and inflammatory disorders |
| J. Boyer et al., 2007 | Yes | Primary human monocytes (in vitro) | Signal transduction, Binding/neutralization | Chronic inflammatory diseases, rheumatoid arthritis |
| Shi Hu et al., 2014 | Yes | Structural studies (crystallography) | Binding/neutralization (epitope binding, receptor blockade) | TNF-alpha-associated diseases |
| Chong Shen et al., 2006 | No | THP-1 cells, SCID-Beige mice (in vitro and in vivo) | Binding/neutralization, Cytotoxic effects | Crohn’s disease and rheumatoid arthritis |
| B. Harvey & Z. Kaymakcalan, 2014 | No | Primary human osteoclast precursors (in vitro) | Binding/neutralization (receptor blockade) | TNF-alpha-related conditions |
| F. Prattichizzo et al., 2016 | Yes | HUVECs, MCF-7 cells, CACs from psoriasis patients (in vitro and human) | Binding/neutralization, Cellular regulation, Tissue/organ effects | Psoriasis, endothelial senescence |

## Thematic Analysis of Adalimumab Mechanisms

### Molecular Binding and TNF-Alpha Sequestration

### Cytotoxic Mechanisms

### Signal Transduction and Pathway Modulation

### NF-κB Pathway Regulation

### MAPK Pathway Effects

### CD36 and Lipid Metabolism

### MicroRNA Modulation

### Cellular Regulation and Phenotype Modulation

### Monocyte Regulation

### Endothelial Function

### Osteoclast Inhibition

## Comparative Mechanisms Among Anti-TNF Agents

### Clinical Implications of Mechanistic Findings

### Therapeutic Efficacy Mechanisms

### Biomarker Potential

### Resistance Mechanisms

### Cardiovascular and Bone Protection

### Anti-Aging and Cancer-Related Effects

## Synthesis

The mechanistic studies reveal adalimumab functions through five complementary mechanisms: (1) direct TNF-alpha sequestration via high-affinity binding to soluble and transmembrane forms, (2) cytotoxic elimination of transmembrane TNF-alpha-expressing cells through CDC, ADCC, and caspase-mediated apoptosis, (3) reverse signaling through transmembrane TNF-alpha inducing cell cycle arrest, (4) modulation of intracellular signaling cascades including NF-κB and MAPK pathways, and (5) epigenetic regulation through microRNA modulation.

### References

[Shi Hu et al. (2013). Comparison of the Inhibition Mechanisms of Adalimumab and Infliximab in Treating Tumor Necrosis Factor α-Associated Diseases from a Molecular View. Journal of Biological Chemistry](/content/review/5a9a7606-a04a-4f18-9157-aedbd5b5a022/source/ss-25345841/index.html)

[Carlos Zamora-Atenza et al. (2014). Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis. Arthritis Research & Therapy](/content/review/5a9a7606-a04a-4f18-9157-aedbd5b5a022/source/ss-933102/index.html)

[Raghav Oberoi et al. (2016). Targeting Tumor Necrosis Factor-α with Adalimumab: Effects on Endothelial Activation and Monocyte Adhesion. PLoS ONE](/content/review/5a9a7606-a04a-4f18-9157-aedbd5b5a022/source/ss-2280715/index.html)

[H. Mitoma et al. (2008). Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis & Rheumatism](/content/review/5a9a7606-a04a-4f18-9157-aedbd5b5a022/source/ss-24600843/index.html)

[J. Boyer et al. (2007). Tumor necrosis factor alpha and adalimumab differentially regulate CD36 expression in human monocytes. Arthritis Research & Therapy](/content/review/5a9a7606-a04a-4f18-9157-aedbd5b5a022/source/ss-17983665/index.html)

[Shi Hu et al. (2014). Comparison of the inhibition mechanisms of Adalimumab and Infliximab in treating tumor necrosis factor α-associated diseases from a molecular view. Journal of Biological Chemistry](/content/review/5a9a7606-a04a-4f18-9157-aedbd5b5a022/source/ss-203656437/index.html)

[Chong Shen et al. (2006). Caspase activation and apoptosis induction by adalimumab: Demonstration in vitro and in vivo in a chimeric mouse model. Inflammatory Bowel Diseases](/content/review/5a9a7606-a04a-4f18-9157-aedbd5b5a022/source/ss-38560819/index.html)

[B. Harvey & Z. Kaymakcalan (2014). SAT0550 Inhibition of Tnf-Enhanced Human Osteoclast Function by Adalimumab is Influenced by Complex Formation in the Absence of FC Receptor Binding. Annals of the Rheumatic Diseases](/content/review/5a9a7606-a04a-4f18-9157-aedbd5b5a022/source/ss-75510138/index.html)

[F. Prattichizzo et al. (2016). Anti-TNF-α treatment modulates SASP and SASP-related microRNAs in endothelial cells and in circulating angiogenic cells. OncoTarget](/content/review/5a9a7606-a04a-4f18-9157-aedbd5b5a022/source/ss-18499509/index.html)

[Aleksandra Plata-Babula et al. (2025). Modulation of Nuclear Factor Kappa B Signaling and microRNA Profiles by Adalimumab in LPS-Stimulated Keratinocytes. International Journal of Molecular Sciences](/content/review/5a9a7606-a04a-4f18-9157-aedbd5b5a022/source/ss-282162793/index.html)